HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilder, B. J. Articles by Buchanan, R. A. Search for Related Content PubMed PubMed Citation Articles by Wilder, B. J. Articles by Buchanan, R. A.

Methsuximide for refractory complex partial seizures

From the Neurology Service, VA Hospital, and the Department of Neurology and Neuroscience, University of Florida College of Medicine, Gainesville, FL (Dr. Wilder), and the Clinical Research Department, Warner-Lamberti/Parke-Davis Company, Ann Arbor, MI (Dr. Buchanan).

The efficacy and safety of methswimide were evaluated for 12 weeks in 21 patients with complex partial (psychomotor) seizures refractory to conventional anticonvulsants. After addition of methsuximide to the previous anticonvulsant regimens, the number of complex partial seizures per patient decreased from a weekly average of 5.8 to 0.9 seizures. A 90 to 100% control of complex partial seizures was achieved in 15 (71%) of the patients. Dose reduction or discontinuation of one or more previous medications was possible in 42%. Seizure control was optimal at methsuximide doses of 9.5 to 11.0 mg per kilogram per day and plasma levels of 20 to 24 µg per milliliter. Adverse experiences, particularly somnolence and lethargy, were reported by 12 patients. Methsuximide appeared to be an effective and generally well tolerated adjunct medication in the management of complex partial seizures.

Address correspondence and reprint requests to Dr. Buchanan, Director. Clinical Research Department, Warner-Larnbet-(Parkr-Davis Company, Ann Arbor, MI 18105.

Accepted for publication September 23, 1980.

This article has been cited by other articles:

				J. C. Gomora, A. N. Daud, M. Weiergraber, and E. Perez-Reyes Block of Cloned Human T-Type Calcium Channels by Succinimide Antiepileptic Drugs Mol. Pharmacol., November 1, 2001; 60(5): 1121 - 1132. [Abstract] [Full Text] [PDF]